Czech National Bank Purchases 27,039 Shares of Merck & Co., Inc. $MRK

Czech National Bank raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 4.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 703,007 shares of the company’s stock after acquiring an additional 27,039 shares during the period. Czech National Bank’s holdings in Merck & Co., Inc. were worth $90,336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRK. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $25,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $31,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

MRK stock opened at $128.27 on Friday. The stock has a market cap of $316.81 billion, a PE ratio of 102.62, a P/E/G ratio of 5.14 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.05. The company has a 50-day moving average price of $123.78 and a 200 day moving average price of $119.04. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 2.72 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRK. Wells Fargo & Company upped their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. CICC Research initiated coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price for the company. Guggenheim boosted their target price on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research report on Wednesday. UBS Group boosted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Thirteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $134.56.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increase: Guggenheim raised its Merck price target from $145 to $146 and maintained a Buy rating, implying meaningful upside from the referenced share price. This reinforces positive Wall Street sentiment. Benzinga
• Positive Sentiment: Keytruda gains another approval: Health Canada approved Keytruda with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s use and potentially supporting sales before its major patent expirations. Health Canada approves Keytruda treatment
• Positive Sentiment: Pipeline and post-Keytruda strategy: Merck’s second-quarter commentary highlighted new product launches, pipeline progress and efforts to diversify into areas including vaccines, infectious diseases, hematology, cardiopulmonary disease and obesity. The company also raised its 2026 sales outlook, improving confidence in near-term execution. MRK Q2 earnings call
• Neutral Sentiment: Dividend comparison: Merck’s latest results have renewed debate over whether it offers a better income opportunity than Pfizer. The discussion may attract dividend-focused investors, but it does not represent a new company-specific catalyst. Pfizer or Merck dividend comparison
• Negative Sentiment: Keytruda patent risk remains central: Keytruda is approaching a significant patent cliff beginning in 2028. Merck is accelerating acquisitions and partnerships to offset the eventual revenue decline, but those investments can pressure earnings and increase execution risk. Merck is racing beyond Keytruda
• Negative Sentiment: Mixed pipeline development: Merck discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease, although the drug continues to be evaluated in other indications. The setback highlights clinical-development risk as Merck builds its post-Keytruda portfolio. MSD anti-TL1A trial update

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.